The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Open accessAbstract
Immunotherapy has demonstrated impressive outcomes for some patients with cancer. However, selecting patients who are most likely to respond to immunotherapy remains a clinical challenge. Here, we discuss immune escape mechanisms exploited by cancer and present strategies for applying this knowledge to improving the efficacy of cancer immunotherapy. Clin Cancer Res; 21(4); 687–92. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many patients may fail to respond to immune checkpoint inhibitors because of the coexistence of other mechanisms of immune evasion, such as the production of adenosine, which binds to its cognate receptor on T cells to trigger apoptosis (13), or the absence of sufficient T and NK cells in the tumor to serve as targets for anti-PD1 (14).”
From HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy (2022) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135 · cited 1×
“In colorectal carcinoma, high densities of CD8þ and CD45ROþ cells predicts decreased tumor recurrence and improved survival in patients with early-stage disease (38).”
BackgroundSpranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Highfill, S. L., Cui, Y., Giles, A. J., Smith, J. P., Zhang, H., Morse, E., Kaplan, R. N., & Mackall, C. L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007974 · Cited by 767 · cited 1×
“In support of this approach, Highfill and colleagues recently demonstrated a role for inhibiting the trafficking of myeloid suppressor cells into tumors by disruption of CXCR2 signaling as a strategy for unveiling the antitumor activity of anti–PD-1 therapy (34).”
BackgroundWeber, J. S., Kudchadkar, R. R., Yu, B., Gallenstein, D., Horak, C. E., Inzunza, H. D., Zhao, X., Martinez, A. J., Wang, W., Gibney, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4802 · Cited by 535
Research works printed but not linked: 32
- Kalos, 2013, Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology, Immunity, 39, 49, 10.1016/j.immuni.2013.07.002 · DOI
- Hamid, 2013, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N Engl J Med, 369, 134, 10.1056/NEJMoa1305133 · DOI
- Burnet, 1970, The concept of immunological surveillance, Prog Exp Tumor Res, 13, 1, 10.1159/000386035 · DOI
- Thomas, 1982, On immunosurveillance in human cancer, Yale J Biol Med, 55, 329
- Schreiber, 2011, Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science, 331, 1565, 10.1126/science.1203486 · DOI · Paper page
- Ferrone, 2010, Dual roles for immunity in gastrointestinal cancers, J Clin Oncol, 28, 4045, 10.1200/JCO.2010.27.9992 · DOI
- Chen, 2013, Oncology meets immunology: the cancer-immunity cycle, Immunity, 39, 1, 10.1016/j.immuni.2013.07.012 · DOI · Paper page
- Coulie, 2014, Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy, Nat Rev Cancer, 14, 135, 10.1038/nrc3670 · DOI
- Tran, 2014, Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer, Science, 344, 641, 10.1126/science.1251102 · DOI
- Robbins, 2013, Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells, Nat Med, 19, 747, 10.1038/nm.3161 · DOI
- van Rooij, 2013, Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma, J Clin Oncol, 31, e439, 10.1200/JCO.2012.47.7521 · DOI · Paper page
- Matsushita, 2012, Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting, Nature, 482, 400, 10.1038/nature10755 · DOI
- Campoli, 2008, HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance, Oncogene, 27, 5869, 10.1038/onc.2008.273 · DOI
- Chang, 2005, Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions, Adv Cancer Res, 93, 189, 10.1016/S0065-230X(05)93006-6 · DOI
- Garrido, 1993, Natural history of HLA expression during tumour development, Immunol Today, 14, 491, 10.1016/0167-5699(93)90264-L · DOI
- Johnsen, 1999, Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis, J Immunol, 163, 4224, 10.4049/jimmunol.163.8.4224 · DOI
- Sconocchia, 2014, HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker, Neoplasia, 16, 31, 10.1593/neo.131568 · DOI
- Kitamura, 2006, Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus calmette-guerin immunotherapy for bladder cancer, Clin Cancer Res, 12, 4641, 10.1158/1078-0432.CCR-06-0595 · DOI
- Shehata, 2009, Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy, Br J Cancer, 101, 1321, 10.1038/sj.bjc.6605315 · DOI
- Taube, 2012, Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape, Sci Transl Med, 4, 127ra37, 10.1126/scitranslmed.3003689 · DOI · Paper page
- Taube, 2014, Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy, Clin Cancer Res, 20, 5064, 10.1158/1078-0432.CCR-13-3271 · DOI · Paper page
- Inozume, 2010, Selection of CD8+PD-1 +lymphocytes in fresh human melanomas enriches for tumor-reactive T cells, J Immunother, 33, 956, 10.1097/CJI.0b013e3181fad2b0 · DOI
- Le Mercier, 2014, VISTA Regulates the Development of Protective Antitumor Immunity, Cancer Res, 74, 1933, 10.1158/0008-5472.CAN-13-1506 · DOI
- Coussens, 2013, Neutralizing tumor-promoting chronic inflammation: a magic bullet?, Science, 339, 286, 10.1126/science.1232227 · DOI
- Mellor, 2008, Creating immune privilege: active local suppression that benefits friends, but protects foes, Nat Rev Immunol, 8, 74, 10.1038/nri2233 · DOI
- DeNardo, 2011, Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy, Cancer Discov, 1, 54, 10.1158/2159-8274.CD-10-0028 · DOI · Paper page
- Lesokhin, 2012, Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment, Cancer Res, 72, 876, 10.1158/0008-5472.CAN-11-1792 · DOI
- Laskey, 2014, A mechanistic theory to explain the efficacy of antiretroviral therapy, Nat Rev, 12, 772
- Holmgaard, 2013, Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4, J Exp Med, 210, 1389, 10.1084/jem.20130066 · DOI
- Galon, 2006, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, 313, 1960, 10.1126/science.1129139 · DOI · Paper page
- Galon, 2013, The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures, Immunity, 39, 11, 10.1016/j.immuni.2013.07.008 · DOI
- Le, 2013, Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer, J Immunother, 36, 382, 10.1097/CJI.0b013e31829fb7a2 · DOI
Cited by
Sorted by citations
Zhu, J.-Y., Zheng, D.-W., Zhang, M.-K., Yu, W.-Y., Qiu, W.-X., Hu, J.-J., Feng, J., & Zhang, X.-Z. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b02786 · Cited by 498
The emerging role of epigenetic therapeutics in immuno-oncology
Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433
Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy
Li, A., Yi, M., Qin, S., Song, Y., Chu, Q., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0721-x · Cited by 413
Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer
Li, C., Xu, X., Wei, S., Jiang, P., Xue, L., & Wang, J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001341 · Cited by 360
CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial
Wang, Y., Chen, M., Wu, Z., Tong, C., Dai, H., Guo, Y., Liu, Y., Huang, J., Lv, H., Luo, C., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1440169 · Cited by 338
Beatty, G. L., O'Dwyer, P. J., Clark, J., Shi, J. G., Bowman, K. J., Scherle, P. A., Newton, R. C., Schaub, R., Maleski, J., Leopold, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2272 · Cited by 314
Self-citationHudson, K., Cross, N., Jordan-Mahy, N., & Leyland, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.568931 · Cited by 243
Cytotoxic T-cells mediate exercise-induced reductions in tumor growth
Rundqvist, H., Veliça, P., Barbieri, L., Gameiro, P. A., Bargiela, D., Gojkovic, M., Mijwel, S., Reitzner, S. M., Wulliman, D., Ahlstedt, E., et al. (2020) · eLife · doi:10.7554/elife.59996 · Cited by 216
Sasidharan Nair, V., Toor, S. M., Ali, B. R., & Elkord, E. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1471137 · Cited by 159
Influence of Androgens on Immunity to Self and Foreign: Effects on Immunity and Cancer
Ben-Batalla, I., Vargas-Delgado, M. E., von Amsberg, G., Janning, M., & Loges, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01184 · Cited by 149
“Tumor cells employ different mechanisms to evade immune elimination, which include: loss of antigenicity, loss of immunogenicity, and orchestration of an immune suppressive microenvironment (133).”
BackgroundChen, J., Harding, S. M., Natesan, R., Tian, L., Benci, J. L., Li, W., Minn, A. J., Asangani, I. A., & Greenberg, R. A. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108080 · Cited by 111
Salman, S., Meyers, D. J., Wicks, E. E., Lee, S. N., Datan, E., Thomas, A. M., Anders, N. M., Hwang, Y., Lyu, Y., Yang, Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156774 · Cited by 111
“Many patients may fail to respond to immune checkpoint inhibitors because of the coexistence of other mechanisms of immune evasion, such as the production of adenosine, which binds to its cognate receptor on T cells to trigger apoptosis (13), or the absence of sufficient T and NK cells in the tumor to serve as targets…”
BackgroundLiang, J., Hänsch, G. M., Hübner, K., & Samstag, Y. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2018.11.006 · Cited by 72
Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy
Yi, M., Jiao, D., Qin, S., Chu, Q., Li, A., & Wu, K. (2019) · Integrative Cancer Therapies · doi:10.1177/1534735419876351 · Cited by 69
Snahnicanova, Z., Kasubova, I., Kalman, M., Grendar, M., Mikolajcik, P., Gabonova, E., Laca, L., Caprnda, M., Rodrigo, L., Ciccocioppo, R., et al. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-019-00601-7 · Cited by 29
Metadata
- Authors
- Beatty, G. L., & Gladney, W. L.
- Affiliations
- Abramson Cancer Center (US)
- Venue
- Clinical Cancer Research
- Published
- 2015-02-15
- Volume
- 21
- Issue
- 4
- Pages
- 687-692
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC4334715
- OpenAlex
- W2030612376
- Cited by
- 1,078
- References
- 10
- Citations by year
- 2026: 30 · 2025: 94 · 2024: 123 · 2023: 155 · 2022: 143 · 2021: 168 · 2020: 138 · 2019: 101 · 2018: 69 · 2017: 31 · 2016: 21 · 2015: 3
- FWCI
- 2.12
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (K08CA138907)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- immune escape mechanisms, cancer immunotherapy, patient selection, treatment response prediction, tumor immune evasion, immunotherapy efficacy
- MeSH terms
- Humans, Immunotherapy, Neoplasms, Tumor Escape
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
